Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data

被引：0
|
作者：
Tingjian Yan
Mallik Greene
Eunice Chang
Ann Hartry
Maëlys Touya
Michael S. Broder
机构：
[1] Partnership for Health Analytic Research,
[2] LLC,undefined
[3] Otsuka Pharmaceutical Development & Commercialization,undefined
[4] Inc.,undefined
[5] Lundbeck,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Adherence; Bipolar I disorder; Long-acting antipsychotics; Neurology; Schizophrenia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1612 / 1625
页数：13
相关论文
共 22 条
  • [1] Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data
    Yan, Tingjian
    Greene, Mallik
    Chang, Eunice
    Hartry, Ann
    Touya, Maelys
    Broder, Michael S.
    ADVANCES IN THERAPY, 2018, 35 (10) : 1612 - 1625
  • [2] Remission and Recovery in Patients With Bipolar I Disorder (BP-I) Treated With Aripiprazole Once-Monthly (AOM 400)
    Madera, Jessica
    Jin, Na
    Amatniek, Joan
    Johnson, Brian
    Baker, Ross A.
    Such, Pedro
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S528 - S528
  • [3] MEDICATION ADHERENCE AND DISCONTINUATION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH ARIPIPRAZOLE ONCE-MONTHLY LONG-ACTING INJECTABLE VERSUS THOSE TREATED WITH ORAL ANTIPSYCHOTICS
    Greene, Mallik
    Yan, Tingjian
    Chang, Eunice
    Hartry, Ann
    Pulasky, Beth
    SCHIZOPHRENIA BULLETIN, 2018, 44 : S248 - S249
  • [4] Effect of aripiprazole once-monthly 400mg (AOM400) on hospitalisation prevention and use of healthcare resources in schizophrenia patients, a study based on real clinical practice on schizophrenia: AMBITION Study
    Sanchez-Gistau, V.
    J. Moreno, M.
    Gomez-Lus, S.
    Sicras Mainar, A.
    Crespo-Facorro, B.
    EUROPEAN PSYCHIATRY, 2023, 66 : S494 - S494
  • [5] Effect of aripiprazole once-monthly 400mg (AOM400) on hospitalisation prevention and use of healthcare resources in schizophrenia patients, a study based on real clinical practice on schizophrenia: AMBITION Study
    Sanchez-Gistau, V.
    Moreno, M. J.
    Gomez-Lus, S.
    Mainar, A. Sicras
    Crespo-Facorro, B.
    EUROPEAN PSYCHIATRY, 2023, 66 : S494 - S494
  • [6] Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA
    Augusto, Margarida
    Greene, Mallik
    Touya, Maelys
    Sweeney, Samantha Min
    Waters, Heidi
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (07) : 627 - 636
  • [7] Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
    Oloruntoba Oluboka
    Guerline Clerzius
    Wolfgang Janetzky
    Daniel Schöttle
    François Therrien
    Klaus Wiedemann
    Marc-André Roy
    BMC Psychiatry, 23
  • [8] Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
    Oluboka, Oloruntoba
    Clerzius, Guerline
    Janetzky, Wolfgang
    Schoettle, Daniel
    Therrien, Francois
    Wiedemann, Klaus
    Roy, Marc-Andre
    BMC PSYCHIATRY, 2023, 23 (01)
  • [9] Once-monthly paliperidone palmitate versus daily oral antipsychotics delays adverse real-world consequences of schizophrenia
    Starr, H.
    Mao, L.
    Rodriguez, S.
    Alphs, L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S550 - S551
  • [10] Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400mg in bipolar I disorder in the USA
    Augusto, Margarida
    Greene, Mallik
    Touya, Maelys
    Sweeney, Samantha Min
    Waters, Heidi
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (07) : 637 - 650
123